50
hypothalamus [4] . Evidence from animal and cell culture experiments strongly suggests that SFFAs 51 are involved in the development of chronic inflammation and insulin resistance in the ARC,
52
disrupting the regulation of whole-body energy homeostasis.
53
In rodents obesity causes hypothalamic inflammation (involving the c-Jun NH2-terminal kinase
54
(JNK) and the IκB kinase β (IKKβ)/ nuclear factor-κB (NFκB) cascades) and insulin resistance [5] [6] [7] [8] .
55
Inhibition of these pro-inflammatory pathways overcomes high-fat diet (HFD)-induced insulin 56 resistance, indicating that inflammation is involved in the development of insulin resistance [5, 9, 10] . 
65
The predominant fatty acid in a typical Western style HFD is the saturated fatty acid palmitate, 
68
induced hypothalamic inflammation and insulin resistance in rats [5] . In contrast, there is evidence 69 from animal models that monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids 
80
C2C12 muscle cells [17] [18] [19] [20] [21] , and the MUFA oleate prevented palmitate-induced inflammation and 81 insulin resistance in N2a neuronal cells [22] .
82
In the present study, we utilized the AgRP-expressing murine hypothalamic cell line mHypoA-83 2/30 to gain insights into the early influences of fatty acids on hypothalamic inflammation and insulin 84 resistance, by conducting time-course experiments. We observed that the palmitate-induced increase 85 of the inflammatory markers pJNK and pNFkB-p65 occurred prior to the development of palmitate-86 induced insulin resistance. Interestingly, we found that palmitate itself is able to moderately activate 87 the PI3K/AKT pathway, prompting us to temporarily inhibit this pathway using p110alpha and 88 p110beta PI3K isoform selective inhibitors. We found that palmitate-induced insulin resistance was 89 abrogated by this temporary inhibition of PI3K. Testing the protective effect of DHA against 90 palmitate-induced inflammation and insulin resistance revealed that DHA was able to prevent 91 palmitate-induced inflammation, and insulin resistance. Surprisingly, DHA showed opposing effects 92 at different time points. While DHA showed no effect on palmitate-induced increase of pNFkB-p65 93 at early phases, DHA itself elevated the protein levels of pJNK as well as of pAKT early in the time-
94
course, but prevented palmitate-induced increase of pJNK, pNFkB-p65 and pAKT later in the time-
95
course. 
97

109
For experiments involving PI3K inhibition using the selective PI3K inhibitors PIK-75 and TGX- 
115
To prepare samples for analysis, the cells were washed once with cold phosphate buffered saline 116 (PBS), followed by lysis of the cells via lysis buffer (RIPA lysis buffer containing 1 x protease inhibitor 117 cocktail; Complete, Roche, Mannheim, Germany), 1 mM Na3VO4 and 20 mM NaF (Sigma-Aldrich, St
118
Louis, MO USA)).
119
All experiments were repeated three times independently to obtain biological triplicates for 120 analysis. 
137
St Giles, UK), followed by blocking of the membrane with Tris-buffered saline with 0.1% Tween20
138
(TBS-T) containing 5% nonfat dry milk (Allpharm, Messel, Germany) for one hour. The membranes
139
were incubated with the following primary antibodies (Cell Signaling Technology, Danvers, MA,
140
USA) in TBS-T over night at 4°C: pAKT (Ser473) (1:1000), total AKT ( 1:000), pNFκB-p65 (Ser536)
141
(1:1000), pJNK (Thr183/Tyr185) (1:1000) and GAPDH (1:10000). The membranes were washed three 
144
washing steps, the membranes were incubated with enhanced chemiluminescence (ECL) solution for 145 2 minutes and subsequently exposed to X-ray hyperfilms (Fujifilm, Minato, Tokio, Japan).
146
Densitometrical quantification of the proteins was performed by using the software ImageJ (Wayne 
159
The data are presented as the means ±SEM of triplicates and differences were considered 160 significant if p ≤ 0.05. The data were analyzed via SigmaPlot (Jandel Corporation, Erkrath, Germany)
161
and statistical significance was determined using one-way ANOVA with post hoc test (Holm-Sidak).
162
Where data failed equal variance or normality tests, they were analyzed by one-way ANOVA on 
165
Palmitate induces insulin resistance in hypothalamic neurons
166
There is strong evidence that high circulating levels of saturated free fatty acids are associated 167 with the development of hypothalamic inflammation and insulin resistance. We investigated 
192
Docosahexaenoic acid and oleate prevent palmitate-induced insulin resistance
193
We next investigated the potential of MUFAs or PUFAs to counteract the pathogenic effects of 194 palmitate. We investigated the effects of co-incubation with DHA, the ω-6 polyunsaturated fatty acid 195 linoleate or the ω-9 monounsaturated fatty acid oleate, on palmitate-induced insulin resistance. We 
236
Palmitate increases pAKT in hypothalamic neurons
237
We next investigated whether palmitate treatment might alter the level of pAKT in the absence 238 of insulin. To assess whether palmitate is able to directly influence the PI3K/AKT pathway, we treated (Fig. S1 ).
256
Docosahexaenoic acid prevents palmitate-induced insulin resistance
257
Having established that of the unsaturated fatty acids we tested, DHA had the most profound 258 effect against palmitate-induced insulin resistance, we further investigated this effect of DHA. 
309
Inhibition of PI3K prevents palmitate-induced insulin resistance
310
To test whether or not the palmitate-induced increase of pAKT is involved in palmitate-induced 319 320 
357
Palmitate led to an increase in the level of pNFκB-p65 by about 2.5 fold compared with control
358
after 8 h (p ≤ 0.001, Figure 8a ). DHA alone had no effect on pNFκB-p65, and co-incubation of DHA
359
with palmitate did not prevent the palmitate-induced increase in pNFκB-p65 at this time point (p = 360 0.008 for PA + DHA vs. Ctrl). After 12 h, palmitate was still able to increase levels of pNFκB-p65 (p = 361 0.002), whereas DHA had no effect (Figure 8b ). However, co-administration of DHA and palmitate
362
led to a decrease in levels of pNFκB-p65 to below the levels of control treated cells (PA + DHA vs.
363
PA: p ≤ 0.001; PA + DHA vs. Ctrl: p = 0.007). This result suggests that DHA prevents palmitate-
364
induced upregulation of pNFκB-p65.
365
Levels of pJNK protein were markedly increased (about 6 fold) after 8 h treatment with either 
368
DHA: p = 0.007). After 12 h of palmitate treatment the level of pJNK protein was similar to levels 369 observed at 8 h, about 6 fold higher than control (P ≤ 0.001) (Figure 8d ). In the presence of DHA alone 370 levels of pJNK were lower compared to the palmitate treated cells, but did not return to baseline
371
(DHA vs. Ctrl: p = 0.004). Similar to the results for pNFκB-p65, co-administration of both fatty acids 372 led to a more profound reduction in pJNK, however, levels remained higher than control (p = 0.009).
373
This suggests that DHA partially protects from palmitate-induced upregulation of pJNK.
Discussion
375
We used an AgRP expressing hypothalamic cell line to study the time course of fatty acids 
401
The unexpected observation that palmitate increased pAKT levels independently of insulin
402
suggests that palmitate might activate the PI3K/AKT pathway. It is therefore plausible that activation 
417
Like palmitate, DHA also increased pAKT protein levels, with the strongest effect detected after 
433
This result indicates that both fatty acids are able to activate the PI3K pathway, and that this 434 activation is involved in the DHA-and palmitate-mediated increase of Gnrh mRNA expression [30] .
435
In another study the same group reported that pretreatment of the hypothalamic cell line rHypoE-7
436
with 100 µM DHA for 1 h prior to TNFα treatment for 10 min led to an increase in pAKT protein level 
455
Our experiments revealed a protective effect of DHA against palmitate-induced inflammation
456
which was time-dependent. While palmitate increased the level of pNFκB-p65, DHA alone did not.
457
Combined administration of palmitate and DHA required 12 h of treatment to reverse the effect of 458 palmitate, whereas 8 h of treatment had no effect. A similar phenomenon was observed for pJNK 459 levels within 12 hours of treatment, but after 8 hours, combined administration of palmitate and DHA
460
increased protein levels of pJNK to levels higher than observed after treatment with either of these 461 fatty acids alone. Nevertheless, our findings suggest that co-treatment with DHA for 12 h protects 462 against palmitate-induced pro-inflammatory signaling via the NFκB-p65 and JNK pathways. 
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